BioMarin (BMRN) is trading lower as investors react to an announced pause of VOXZOGO dosing across three Phase 2 indications after SCFE events were observed. While the company emphasized broader safety experience in achondroplasia, the market is treating the update as a meaningful derisking event for VOXZOGO’s label-expansion strategy and near-term growth narrative. (fr.tradingview.com)

VOXZOGO is central to BioMarin’s growth expectations, so any disruption to development in additional indications can pressure sentiment even if the commercial achondroplasia franchise remains intact. The pause increases uncertainty around the timing and probability of incremental VOXZOGO opportunities that investors often model into medium-term revenue growth, which can translate quickly into multiple compression on a down day.

Key next steps include BioMarin’s follow-up disclosure on the scope of the SCFE findings, any protocol amendments, and whether dosing resumes after additional monitoring or risk-mitigation measures. Investors will also be focused on whether BioMarin adjusts its VOXZOGO outlook within its 2026 framework as it continues executing on broader strategic priorities, including its planned Q2 2026 closing of the Amicus Therapeutics acquisition. (finance.yahoo.com)